Orlistat
Metabolic Health · Lipase inhibitor
Tier B
lipase-inhibitorotc
6.9 / 10
Tier B
Ev 8.0 Bn 3.5 Sf 7.0
What this is
XENDOS trial: modest weight loss (~3% above placebo at 4 years) and ~37% reduction in progression to T2D. Steatorrhea and "anal leakage" are common and notorious. Now largely displaced by GLP-1 era drugs.
Mechanism
Inhibits pancreatic/gastric lipases — prevents absorption of ~30% of dietary fat; unabsorbed fat excreted in stool
Dose & route
60 mg (OTC) or 120 mg TID with meals
Citations
- https://pubmed.ncbi.nlm.nih.gov/14693982/
- https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004094/full
- https://pubmed.ncbi.nlm.nih.gov/18779402/
- https://clinicaltrials.gov/study/NCT01755676
- https://clinicaltrials.gov/study/NCT00212199
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.